The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A randomized double-blind placebo-controlled study to assess the prevention of low-dose acetylsalicylic acid (ASA) associated gastroduodenal lesions and upper gastrointestinal symptoms in patients taking esomeprazole 20 mg once daily (od) for 26 weeks
- collapse A randomised, double-blind, double dummy, multicentre study to evaluate the efficacy and safety of esomeprazole 40 mg given i.v. or orally o.d. for 1 week to subjects with erosive reflux esophagitis, followed by 3 weeks' open oral treatment with esomeprazole 40 mg o.d.
- collapse A Randomised, Double-Blind, Placebo Controlled Explorative Study to Investigate the Efficacy and Safety of Esomeprazole in the Prevention of Post Operative Nausea and Vomiting
- collapse An Open, Randomized, Two-Way Crossover Study Comparing the Effect of 20 mg Esomeprazole Administered Orally and Intravenously as a 3-minute Injection on Basal and Pentagastrin-Stimulated Acid Output in Patients with Symptoms of Gastroesophageal Reflux Disease (GERD)
- collapse An Open, Randomized, Two-Way Crossover Study Comparing the Effect of 40 mg Esomeprazole Administered Orally and Intravenously as a 3-minute Injection on Basal and Pentagastrin-Stimulated Acid Output in Patients with Symptoms of Gastroesophageal Reflux Disease (GERD)
- collapse A Phase III, Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety of Once Daily Esomeprazole for the Treatment of Clinically Diagnosed Gastroesophageal Reflux Disease (GERD) in Pediatric and Adolescent Patients 12 to 17 Years of Age, Inclusive
- collapse A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive
- collapse A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Infants Aged 1 to 11 Months, Inclusive
- collapse A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Single Oral Doses of Esomeprazole Magnesium in Pediatric Patients 1 to 11 Years-Old Inclusive with Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)
- collapse Randomised, double-blind, placebo-controlled multicenter study to assess management strategies in the treatment of Helicobacter pylori infected patients with gastro-oesophageal reflux disease (GERD)
